The ADC consists of a c-MET antibody linked to a microtubule inhibitor and was given FDA breakthrough therapy designation for EGFR wild-type NSCLC following initial data from the ongoing phase II LUMINOSITY trial. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.